In septic patients with acute renal failure, SepteX has been shown to decrease plasma concentrations of IL-6 and IL-1 receptor antagonist (IL-1ra), correct immune dysfunction and reduce the need for vasopressor support compared to standard renal replacement therapies [35], [36], [37]. Here, IL6 is linked to acute kidney injury.